84 results on '"Fernández-Martos, C."'
Search Results
2. Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial
- Author
-
Fernandez-Martos, C., Garcia-Albeniz, X., Pericay, C., Maurel, J., Aparicio, J., Montagut, C., Safont, M.J., Salud, A., Vera, R., Massuti, B., Escudero, P., Alonso, V., Bosch, C., Martin, M., and Minsky, B.D.
- Published
- 2015
- Full Text
- View/download PDF
3. SEOM/SERAM consensus statement on radiological diagnosis, response assessment and follow-up in colorectal cancer
- Author
-
García-Carbonero, R., Vera, R., Rivera, F., Parlorio, E., Pagés, M., González-Flores, E., Fernández-Martos, C., Corral, M. Á., Bouzas, R., and Matute, F.
- Published
- 2017
- Full Text
- View/download PDF
4. SEOM Clinical Guideline of localized rectal cancer (2016)
- Author
-
González-Flores, E., Losa, F., Pericay, C., Polo, E., Roselló, S., Safont, M. J., Vera, R., Aparicio, J., Cano, M. T., and Fernández-Martos, C.
- Published
- 2016
- Full Text
- View/download PDF
5. 442P A phase I-II multicenter trial with avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients. GEMCAD 16-02 (AVEVAC trial)
- Author
-
Español-Rego, M., primary, Fernández-Martos, C., additional, Fernandez, M.E. Elez, additional, Foguet, C., additional, Pedrosa, L., additional, Rodríguez, N., additional, Ruiz, A., additional, Pineda, E., additional, Cid, J., additional, Cabezón, R., additional, Oliveres, H., additional, Lozano, M., additional, Ginés, A., additional, Garcia-Criado, A., additional, Cuatrecasas, M., additional, Torres, F., additional, Cascante, M., additional, Benítez-Ribas, D., additional, and Maurel, J., additional
- Published
- 2021
- Full Text
- View/download PDF
6. 605P First-line chemotherapy with or without targeted therapies in metastatic colorectal cancer: The GEMCAD 14-01 prospective cohort
- Author
-
Oliveres, H., Alonso-Orduna, V., Feliu, J., Fernandez Montes, A., Martin-Richard, M., Galvez Munoz, E., Ruiz-Casado, A., Yubero Esteban, A., Aparicio, J., Alcaide-Garcia, J., Gallego Plazas, J., Carmona-Bayonas, A., Fernandez Martos, C., Gallego, M.R., Manzano Alemany, H., Leno, R., Esposito, F.M., Sapena, V., and Maurel, J.
- Published
- 2023
- Full Text
- View/download PDF
7. 595P The DUREC trial: Durvalumab plus total neoadjuvant therapy in locally advanced rectal cancer - a multicenter, single-arm, phase II study (GEMCAD-1703)
- Author
-
Capdevila Castillon, J., Alonso, V., Macias Declara, I., Melian, M., Gallego Plazas, J., Vera, R., Riesco Martinez, M.C., Maurel, J., Grana Suarez, B., Hernando, J., Garcia Alvarez, A., Navalpotro, B., Soler Gonzalez, G., Polo, E., Garcia Fadrique, A., Espin, E., Fernandez Martos, C., Villacampa Javierre, G., and Losa, F.
- Published
- 2023
- Full Text
- View/download PDF
8. 474P Prognostic and predictive role of Consensus Molecular Subtypes (CMS) determined by immunohistochemistry in metastatic colorectal cancer (mCRC)
- Author
-
Gomez, O. Higuera, primary, Soto, V. Heredia, additional, Machado, I., additional, Mendez, M.C., additional, Cuatrecasas, M., additional, Horndler, C., additional, Vermeulen, L., additional, Hoorn, S. Ten, additional, Mendiola, M., additional, Martín-Richard, M., additional, Ruiz-Casado, A., additional, Galvez, E., additional, Aparicio, J., additional, García, I. Sevilla, additional, Leno, R., additional, Fernández-Martos, C., additional, Alonso-Orduna, V., additional, Montes, A. Fernandez, additional, Maurel, J., additional, and Feliu, J., additional
- Published
- 2020
- Full Text
- View/download PDF
9. 471P Identification and validation of a new prognostic score in metastatic colorectal cancer (mCRC): GEMCAD score
- Author
-
Seguí, E., primary, Alonso-Orduna, V., additional, Sesma, A., additional, Martin-Richard, M., additional, Salud, A., additional, Fernández-Montes, A., additional, Fernández-Martos, C., additional, Ruiz-Casado, A., additional, Gallego, J., additional, Aparicio, J., additional, Gálvez, E., additional, Manzano, H., additional, Alcaide-Garcia, J., additional, Gallego, R., additional, Falco, E., additional, Esposito, F., additional, Oliveres, H., additional, Torres, F., additional, Feliu, J., additional, and Maurel, J., additional
- Published
- 2020
- Full Text
- View/download PDF
10. Prospective Biomarker Study in Advanced RAS Wild-Type Colorectal Cancer: POSIBA Trial (GEMCAD 10-02)
- Author
-
García-Albéniz X, Alonso V, Escudero P, Méndez M, Gallego J, Rodríguez JR, Salud A, Fernández-Plana J, Manzano H, Zanui M, Falcó E, Feliu J, Gil M, Fernández-Martos C, Bohn U, Alonso C, Calderero V, Rojo F, Cuatrecasas M, and Maurel J
- Subjects
Clinical score ,Cetuximab ,neoplasms ,Colorectal cancer ,Biomarkers - Abstract
Background RAS testing is used to select patients with anti-epidermal growth factor receptor (EGFR) therapies sensitivity in metastatic colorectal cancer (mCRC). However, other biomarkers such as BRAF, PIK3CA/PTEN, and p-IGF-1R+/MMP7+ (double positive [DP] phenotype) have not been prospectively assessed to predict anti-EGFR resistance. Materials and Methods We designed a multicenter prospective trial (NCT01276379) to evaluate whether the biomarkers BRAF mutation, PIK3CA mutation/PTEN loss, and DP phenotype can improve the prediction for 12-months progression-free survival (PFS) over the use of clinical variables exclusively in patients with RAS wild-type (WT) mCRC treated with standard chemotherapy plus biweekly cetuximab as first-line therapy. The planned sample size was 170 RAS WT patients to detect a 20% difference in 12-month PFS based on the analysis of clinical and selected biomarkers (alpha = .05, beta = .2). The discriminatory capacity of the biomarkers was evaluated using receiver operating characteristic curves. Results We included 181 RAS WT patients. The biomarker distribution was as follows: BRAF mutant, 20 patients (11%); PIK3CA mutated/PTEN loss, 98 patients (58%); DP, 23 patients (12.7%). The clinical variables in the clinical score were progression status >0, left-sided tumor, and resectable liver metastasis as the only metastatic site. The area under the curve (AUC) of the score containing the clinical variables was 0.67 (95% confidence interval [CI], 0.60-0.75). The AUC of the score with clinical variables and BRAF mutational status was 0.68 (0.61-0.75, p = .37). The AUC of the score with clinical variables and PI3KCA mutation/PTEN status was 0.69 (0.61-0.76, p = .32). The AUC of the score with clinical variables and DP phenotype was 0.66 (0.58-0.73, p = .09). Conclusion The addition of BRAF, PIK3CA/PTEN, and DP to a clinical score does not improve the discrimination of 12-month PFS. Implications for Practice This prospective biomarker design study has important clinical implications because many prospective clinical trials are designed with the hypothesis that BRAF mutation per se and MEK and PIK3CA downstream pathways are critical for colorectal tumor survival. The results lead to the question of whether these pathways should be considered as passengers instead of drivers.
- Published
- 2019
11. Multicenter phase II trial evaluating a three-weekly schedule of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer
- Author
-
Aparicio, J., Vicent, J. M., Maestu, I., Garcerá, S., Busquier, I., Bosch, C., Llorca, C., Díaz, R., Fernández-Martos, C., and Galán, A.
- Published
- 2003
12. Clinical impact of circulating tumor RAS and BRAF mutation dynamics in metastatic colorectal cancer patients treated with first-line chemotherapy plus anti-EGFR therapy: Combined analysis of two prospective clinical trials
- Author
-
Montagut, C., primary, Alonso, V., additional, Escudero, P., additional, Fernández-Martos, C., additional, Salud Salvia, A., additional, Méndez, M., additional, Gallego Plazas, J., additional, Rodriguez, J.R., additional, Martín-Richard, M., additional, Fernández-Plana, J., additional, Aparicio, J., additional, Feliu Batlle, J., additional, García de Albéniz, X., additional, Rojo, F., additional, Fernández, V., additional, Claes, B., additional, Maertens, G.G., additional, Sablon, E., additional, Jacobs, B.A.W., additional, and Maurel, J., additional
- Published
- 2018
- Full Text
- View/download PDF
13. Prospective biomarker study in advanced RAS wild-type colorectal cancer: POSIBA trial
- Author
-
García Albéniz, X., primary, Alonso, V., additional, Escudero, P., additional, Méndez, M., additional, Gallego Plazas, J., additional, Rodriguez, J.R., additional, Salud Salvia, A., additional, Fernández-Plana, J., additional, Manzano Alemany, H., additional, Zanui, M., additional, Falcó, E., additional, Feliu Batlle, J., additional, Gil-Raga, M., additional, Fernández-Martos, C., additional, Bohn Sarmiento, U., additional, Alonso López, M.C., additional, Calderero Aragón, V., additional, Rojo, F., additional, Cuatrecasas, M., additional, and Maurel, J., additional
- Published
- 2018
- Full Text
- View/download PDF
14. AVEVAC: A phase I-II trial with avelumab plus autologous dendritic cell (ADC) vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer (mCRC) patients (GEMCAD 16-02)
- Author
-
Español Rego, M., primary, Alonso, V., additional, Aparicio, J., additional, Elez Fernandez, E., additional, Escudero, P., additional, Fernández-Martos, C., additional, Rodríguez, N., additional, Ruiz Casado, A., additional, Cid, J., additional, Cabezón, R., additional, Lozano, M., additional, Ginés, A., additional, Bianchi, L., additional, Garcia-Corbacho, J., additional, García de Albéniz, X., additional, Maurel, J., additional, and Benitez Ribas, D., additional
- Published
- 2018
- Full Text
- View/download PDF
15. Session 2: Are we ready for primary chemotherapy in rectal cancer: who, when, why?
- Author
-
Patel, U. B., primary, Cervantes, A., additional, Fernández-Martos, C., additional, Sclafani, F., additional, Cunningham, D., additional, Nilsson, P., additional, and Brown, G., additional
- Published
- 2018
- Full Text
- View/download PDF
16. P-191 - Randomized phase II clinical trial to evaluate the efficacy of second-line FOLFIRI-panitumumab in patients with RAS wild-type metastatic colorectal cancer who have received FOLFOX-panitumumab in first-line (BEYOND)
- Author
-
Aparicio, J., Virgili, A., Capdevila, J., Muñoz Boza, F., Álvarez, R., Bosch, C., Cámara, J., Fernandez-Martos, C., Fernandez-Plana, J., Gallego, J., Gallego, R., Hernández-Yagüe, X., Macías Declara, I., Rodríguez-Salas, N., Vera, R., Taberner, M., and Maurel, J.
- Published
- 2019
- Full Text
- View/download PDF
17. Aflibercept plus FOLFIRI for 2nd line treatment of metastatic colorectal cancer (mCRC): Long-term safety observation from the global aflibercept safety and quality-of-life (QoL) program (ASQoP)
- Author
-
Riechelmann, R., primary, Srimuninnimit, V., additional, Kavan, P., additional, Di Bartolomeo, M., additional, Maiello, E., additional, Cicin, I., additional, Kröning, H., additional, Garcia-Alfonso, P., additional, Chau, I., additional, Fernández-Martos, C., additional, Ter-Ovanesov, M., additional, Peeters, M., additional, Picard, P., additional, and Bordonaro, R., additional
- Published
- 2016
- Full Text
- View/download PDF
18. SEOM/SERAM consensus statement on radiological diagnosis, response assessment and follow-up in colorectal cancer
- Author
-
García-Carbonero, R., primary, Vera, R., additional, Rivera, F., additional, Parlorio, E., additional, Pagés, M., additional, González-Flores, E., additional, Fernández-Martos, C., additional, Corral, M. Á., additional, Bouzas, R., additional, and Matute, F., additional
- Published
- 2016
- Full Text
- View/download PDF
19. 611TiP - AVEVAC: A phase I-II trial with avelumab plus autologous dendritic cell (ADC) vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer (mCRC) patients (GEMCAD 16-02)
- Author
-
Español Rego, M., Alonso, V., Aparicio, J., Elez Fernandez, E., Escudero, P., Fernández-Martos, C., Rodríguez, N., Ruiz Casado, A., Cid, J., Cabezón, R., Lozano, M., Ginés, A., Bianchi, L., Garcia-Corbacho, J., García de Albéniz, X., Maurel, J., and Benitez Ribas, D.
- Published
- 2018
- Full Text
- View/download PDF
20. 545P - Clinical impact of circulating tumor RAS and BRAF mutation dynamics in metastatic colorectal cancer patients treated with first-line chemotherapy plus anti-EGFR therapy: Combined analysis of two prospective clinical trials
- Author
-
Montagut, C., Alonso, V., Escudero, P., Fernández-Martos, C., Salud Salvia, A., Méndez, M., Gallego Plazas, J., Rodriguez, J.R., Martín-Richard, M., Fernández-Plana, J., Aparicio, J., Feliu Batlle, J., García de Albéniz, X., Rojo, F., Fernández, V., Claes, B., Maertens, G.G., Sablon, E., Jacobs, B.A.W., and Maurel, J.
- Published
- 2018
- Full Text
- View/download PDF
21. 486P - Prospective biomarker study in advanced RAS wild-type colorectal cancer: POSIBA trial
- Author
-
García Albéniz, X., Alonso, V., Escudero, P., Méndez, M., Gallego Plazas, J., Rodriguez, J.R., Salud Salvia, A., Fernández-Plana, J., Manzano Alemany, H., Zanui, M., Falcó, E., Feliu Batlle, J., Gil-Raga, M., Fernández-Martos, C., Bohn Sarmiento, U., Alonso López, M.C., Calderero Aragón, V., Rojo, F., Cuatrecasas, M., and Maurel, J.
- Published
- 2018
- Full Text
- View/download PDF
22. 552P - Aflibercept plus FOLFIRI for 2nd line treatment of metastatic colorectal cancer (mCRC): Long-term safety observation from the global aflibercept safety and quality-of-life (QoL) program (ASQoP)
- Author
-
Riechelmann, R., Srimuninnimit, V., Kavan, P., Di Bartolomeo, M., Maiello, E., Cicin, I., Kröning, H., Garcia-Alfonso, P., Chau, I., Fernández-Martos, C., Ter-Ovanesov, M., Peeters, M., Picard, P., and Bordonaro, R.
- Published
- 2016
- Full Text
- View/download PDF
23. UFT plus or minus calcium folinate for metastatic colorectal cancer in older patients
- Author
-
Díáz-Rubio E, Sastre J, Abad A, Navarro M, Aranda E, Carrato A, Gallén M, Marcuello E, Rifá J, Massuti T, Cervantes A, Antón A, and Fernández Martos C
- Subjects
Aged, 80 and over ,Male ,Liver Neoplasms ,Leucovorin ,Administration, Oral ,Adenocarcinoma ,Survival Rate ,Treatment Outcome ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Drug Therapy, Combination ,Female ,Colorectal Neoplasms ,Uracil ,Aged ,Follow-Up Studies ,Retrospective Studies ,Tegafur - Abstract
Two studies were carried out to determine the activity and evaluate the toxicity of oral chemotherapy with uracil and tegafur in a 4:1 molar ratio (UFT) plus or minus calcium folinate in elderly patients with advanced colorectal cancer. In one study, 106 patients received a fixed dose of UFT 400 mg/day in two daily doses every 12 hours continuously, plus calcium folinate 45 mg/day administered in three divided doses every 8 hours continuously. In study 2, calcium folinate was omitted, and the dose of UFT was increased to 400 mg/m2/day in two daily doses administered every 12 hours continuously to 95 patients. Treatments for both studies were administered until grade 3 or grade 4 toxicity occurred or disease progressed. The response rate among the 96 available patients in study 1 was 17.7% (95% confidence interval [CI], 10% to 27%); 41 patients (43%) achieved an objective response or stable disease. Overall survival was 13.7 months with a statistically significant difference between patients with no progressive disease and patients with progressive disease (P.01). In study 2, 62 of 95 patients have now been evaluated for response. The response rate was 21% (95% CI, 13% to 30%); 38 patients (61%) experienced an objective response or stable disease. The overall survival for study 2 has not yet been evaluated. Toxicity was generally mild, consisting of grade 3 nausea/vomiting (6% in study 1 and 2% in study 2), grade 3 or grade 4 diarrhea (11% in study 1 and 7% in study 2), plus one case of grade 3 mucositis in study 1. These findings suggest that chemotherapy with UFT (with or without modulation with calcium folinate) is feasible for elderly patients with advanced colorectal carcinoma.
- Published
- 1999
24. The Spanish experience with high-dose infusional 5-fluorouracil (5-FU) in colorectal cancer. The Spanish Cooperative Group For Gastrointestinal Tumor Therapy (TTD)
- Author
-
Aranda, E., Cervantes, A., ALFREDO CARRATO, Antón-Torres, A., Massutí, T., Fernández-Martos, C., and Díaz-Rubio, E.
- Subjects
Adult ,Diarrhea ,Male ,Antimetabolites, Antineoplastic ,Dose-Response Relationship, Drug ,Vomiting ,Antidotes ,Carcinoma ,Leucovorin ,Administration, Oral ,Anemia ,Leukopenia ,Middle Aged ,Treatment Outcome ,Spain ,Humans ,Female ,Fluorouracil ,Colorectal Neoplasms ,Infusions, Intravenous ,Aged - Abstract
Background In a previous phase I to II trial, we have shown that the maximum tolerable dose (MTD) of 5-Fluorouracil (5-FU) in 48-hour continuous infusion (CI) weekly was 3.5 gr/m2. In a subsequent confirmative phase II trial with 85 evaluable patients, a 38.5% response rate was obtained and the median survival reached was 12 months. These data were comparable to those achieved by biochemical modulation of 5-FU with Leucovorin. On this basis we tried to modulate high-dose 5-FU (3 gr/m2) with oral leucovorin (LV) but the regimen was too toxic and the dose had to be reduced. A new phase II trial with 2 g/m2/week plus oral leucovorin was planned. Patients received a median dose intensity of 5-FU of 1.6 g/m2/week (range 0.9-2). Three complete responses and 36 partial responses were observed. Overall response rate was 37.5% (95% CI, 28% to 46.8%). Median time to progression has been 7.4 months, and median survival 14.4 months. WHO grade 3 diarrhea was seen in 27 patients (24.5%). Grade 3 mucositis was also seen in 9 (8.1%) patients, and grade 4 was observed in one. Grade 3 nausea and vomiting was reported in 13 (11.7%) patients. Grade 3 hand-foot syndrome was detected in only 5 (4.5%) patients. Grade 4 leukopenia was observed in 1 case and grade 3 to 4 thrombocytopenia was observed in two cases, respectively. Oral leucovorin modulation of weekly 48-hour continuous infusion of 5-FU at 2 g/m2 is an active regimen, with diarrhea and mucositis as main limiting toxicities. Its antitumor activity does not seem superior to that obtained with a weekly 48 hour continuous infusion of 5-FU alone at a dose of 3.5 g/m2.
- Published
- 1996
25. Factors promoting axon growth in the deer antler
- Author
-
Nieto-Diaz, M., primary, Pita-Thomas, W., additional, Maza, R. M., additional, Yunta-Gonzalez, M., additional, Lopez-Rodríguez, M. J., additional, Navarro-Ruiz, R., additional, Reigada, D., additional, Fernández-Martos, C., additional, and Nieto-Sampedro, M., additional
- Published
- 2011
- Full Text
- View/download PDF
26. Serum IGFBP3, IGF-I, and MMP7 changes in advanced colorectal cancer (ACRC) patients (pts) treated with anti-EGFR therapy: A GEMCAD study
- Author
-
Pineda, E., primary, Pericay, C., additional, García-Albéniz, X., additional, Augé, J., additional, Alonso, V., additional, Escudero, P., additional, Fernández-Martos, C., additional, Gallego, R., additional, and Maurel, J., additional
- Published
- 2009
- Full Text
- View/download PDF
27. Phase I trial of cisplatin, infusional 5-FU and irinotecan in advanced gastric cancer
- Author
-
Segura, A., primary, Fernández-Martos, C., additional, Aparicio, J., additional, Campos, J. M., additional, Vicent, J., additional, Busquier, I., additional, Molins, C., additional, and Guillem, V., additional
- Published
- 2004
- Full Text
- View/download PDF
28. 599P - A Validation of Current Prognostic Scores in Metastatic Colorectal Cancer (Mcrc) and a New Prognostic Score (A Gemcad Study)
- Author
-
Alonso-Orduna, V., Marmol, M., Escudero, P., Salud, A., Safont, M.J., Méndez, J.C., Girón, C. García, Martín, M., Fernandez-Martos, C., Albéniz, X. García, Feliu, J., and Maurel, J.
- Published
- 2014
- Full Text
- View/download PDF
29. Outpatient weekly high-dose continuous-infusion 5-fluorouracil plus oral leucovorin in advanced colorectal cancer. A phase II trial
- Author
-
Aranda, E., primary, Barneto, I., additional, Cervantes, A., additional, García-Conde, J., additional, Carrato, A., additional, Barón, J.M., additional, Díaz-Rubio, E., additional, Fernández-Martos, C., additional, Antón-Torres, A., additional, and Massutí, T., additional
- Published
- 1996
- Full Text
- View/download PDF
30. Etoposide (E) + epirebicin (E) + cisplatin (P) combination chemotherapy (EEP) In advanced gastric cancer: Negative impact on clinical outcome
- Author
-
Díaz-Rubio, E., primary, Jimeno, J., additional, Aranad, E., additional, Massuti, B., additional, Camps, C., additional, Cervantes, A., additional, Dorta, J., additional, Hernández, J.J. Cruz, additional, Dominguez, S., additional, Anton, A., additional, Carrato, A., additional, Villar, A., additional, Macheng, I., additional, Alonso, J.D., additional, Fernández Martos, C., additional, González, R., additional, Fonseca, E., additional, Balańa, C., additional, and Sánchez Hernández, J.J., additional
- Published
- 1992
- Full Text
- View/download PDF
31. PG 1.02 Clinically relevant study end points in rectal cancer
- Author
-
Fernandez-Martos, C.
- Published
- 2012
- Full Text
- View/download PDF
32. A phase II trial of weekly high dose continuous infusion 5-fluorouracil plus oral leucovorin in patients with advanced colorectal cancer. The Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD).
- Author
-
Aranda, Enrique, Cervantes, Andrés, Dorta, Javier, Blanco, Esperanza, Fernández-Martos, Carlos, Cruz-Hernandez, Juan José, Carrato, Alfredo, Gonzalez-Mancha, Rosario, García-Conde, Javier, Díaz-Rubio, Eduardo, Aranda, E, Cervantes, A, Dorta, J, Blanco, E, Fernández-Martos, C, Cruz-Hernandez, J J, Carrato, A, Gonzalez-Mancha, R, García-Conde, J, and Díaz-Rubio, E
- Published
- 1995
- Full Text
- View/download PDF
33. A Phase I-II multicenter trial with Avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients; GEMCAD 1602 study
- Author
-
Marta Español-Rego, Carlos Fernández-Martos, Elena Elez, Carles Foguet, Leire Pedrosa, Nuria Rodríguez, Ana Ruiz-Casado, Estela Pineda, Joan Cid, Raquel Cabezón, Helena Oliveres, Miquel Lozano, Angels Ginés, Angeles García-Criado, Juan Ramon Ayuso, Mario Pagés, Miriam Cuatrecasas, Ferràn Torres, Timothy Thomson, Marta Cascante, Daniel Benítez-Ribas, Joan Maurel, Institut Català de la Salut, [Español-Rego M] Immunology Department, Hospital Clínic, Barcelona, Spain. [Fernández-Martos C] Medical Oncology Department, Instituto Valenciano de Oncología, Valencia, Spain. [Elez E] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Foguet C] Department of Biochemistry and Molecular Medicine, Universitat de Barcelona, Barcelona, Spain. [Pedrosa L] Translational Genomics and Targeted Therapeutics in Solid Tumors Group, Medical Oncology Department, Hospital Clinic of Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain. [Rodríguez N] Medical Oncology Department, Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
Vaccines ,ADN - Reparació ,Vacunes contra el càncer ,Cancer Research ,Resistance ,Immunology ,terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS] ,Medicaments antineoplàstics - Ús terapèutic ,Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores] ,Complex Mixtures::Biological Products::Vaccines::Cancer Vaccines [CHEMICALS AND DRUGS] ,Other subheadings::Other subheadings::/drug therapy [Other subheadings] ,neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias intestinales::neoplasias colorrectales [ENFERMEDADES] ,Còlon - Càncer - Tractament ,fenómenos genéticos::reparación del ADN::reparación del emparejamiento incorrecto del ADN [FENÓMENOS Y PROCESOS] ,Metabolism ,Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms [DISEASES] ,Oncology ,Genetic Phenomena::DNA Repair::DNA Mismatch Repair [PHENOMENA AND PROCESSES] ,Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT] ,mezclas complejas::productos biológicos::vacunas::vacunas del cáncer [COMPUESTOS QUÍMICOS Y DROGAS] ,Recte - Càncer - Tractament ,Immunology and Allergy - Abstract
Metabolism; Resistance; Vaccines Metabolisme; Resistència; Vacunes Metabolismo; Resistencia; Vacunas Background Immune check-point blockade (ICB) has shown clinical benefit in mismatch repair-deficient/microsatellite instability high metastatic colorectal cancer (mCRC) but not in mismatch repair-proficient/microsatellite stable patients. Cancer vaccines with autologous dendritic cells (ADC) could be a complementary therapeutic approach to ICB as this combination has the potential to achieve synergistic effects. Methods This was a Phase I/II multicentric study with translational sub-studies, to evaluate the safety, pharmacodynamics and anti-tumor effects of Avelumab plus ADC vaccine in heavily pre-treated MSS mCRC patients. Primary objective was to determine the maximum tolerated dose and the efficacy of the combination. The primary end-point was 40% progression-free survival at 6 months with a 2 Simon Stage. Results A total of 28 patients were screened and 19 pts were included. Combined therapy was safe and well tolerated. An interim analysis (Simon design first-stage) recommended early termination because only 2/19 (11%) patients were disease free at 6 months. Median PFS was 3.1 months [2.1–5.3 months] and overall survival was 12.2 months [3.2–23.2 months]. Stimulation of immune system was observed in vitro but not clinically. The evaluation of basal RNA-seq noted significant changes between pre and post-therapy liver biopsies related to lipid metabolism and transport, inflammation and oxidative stress pathways. Conclusions The combination of Avelumab plus ADC vaccine is safe and well tolerated but exhibited modest clinical activity. Our study describes, for the first-time, a de novo post-therapy metabolic rewiring, that could represent novel immunotherapy-induced tumor vulnerabilities. The study was funded by grants from the FIS PI17/00732 from Instituto de Salud Carlos III, Premi Fi de Residència Emili Letang from Hospital Clínic Barcelona, Plan Nacional de I + D (PID-107139RB-C21 to DB-R and PID2020-115051RB-I00 to MC) and Grupo Español Multidisciplinar en Cáncer Digestivo (GEMCAD). The study was funded with Grants from Catalan Agency for Management of University and Research Grants (AGAUR) (2014-SGR-474, 2017-SGR-1174 and 2017-SGR-1033), Fundació la Marató de TV3 (201330.10), Instituto de Salud Carlos III (PI13/01728 and PI19/00740) and Fundacion Olga Torres (Modalitat A. 2019/2020) to JM. IMMETCOLS signature is under patent protection (EP21382772.8.) This research was financially supported by GEMCAD and (OR Avelumab was provided) by Merck, S.L.U., Madrid, Spain, an affiliate of Merck KGaA, Darmstadt, Germany, as part of an alliance between the healthcare business of Merck KGaA, Darmstadt, Germany (CrossRef Funder ID: https://doi.org/10.13039/100009945) and Pfizer.
- Published
- 2022
34. Role of Kras Status in Patients with Metastatic Colorectal Cancer Receiving First-Line Chemotherapy plus Bevacizumab: A TTD Group Cooperative Study
- Author
-
Eduardo Díaz-Rubio, Auxiliadora Gómez-España, Bartomeu Massutí, Javier Sastre, Margarita Reboredo, José Luis Manzano, Fernando Rivera, M José Safont, Clara Montagut, Encarnación González, Manuel Benavides, Eugenio Marcuello, Andrés Cervantes, Purificación Martínez de Prado, Carlos Fernández-Martos, Antonio Arrivi, Inmaculada Bando, Enrique Aranda, Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD), The Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD), [Díaz-Rubio,E, Sastre,J, Bando,I] Department of Medical Oncology, Hospital Clínico San Carlos (HCSC), Red Temática de Investigación Cooperativa en Cáncer (RD06/0020/0021), Facultad de Medicina, Universidad Complutense, Instituto de Investigación Sanitaria del HCSC (IdISSC), Madrid, Spain. [Gómez-España,A, Aranda,E] Department of Medical Oncology, Hospital Reina Sofía, Córdoba, Spain. [Massutí,B] Department of Medical Oncology, Hospital General, Alicante, Spain. [Reboredo,M] Department of Medical Oncology, Complejo Hospitalario Universitario La Coruña, La Coruña, Spain. [Manzano, JL] Department of Medical Oncology, Instituto Catalán de Oncología, Hospital Germans Trias I Pujol, Badalona, Spain. [Rivera,F] Department of Medical Oncology, Hospital Marqués de Valdecilla, Santander, Spain. [Safont,MJ] Department of Medical Oncology, Hospital General de Valencia, Valencia, Spain. [Montagut,C] Department of Medical Oncology, Hospital del Mar, Barcelona, Spain. [González,E] Department of Medical Oncology, Hospital Virgen de las Nieves, Granada, Spain. [Benavides,M] Department of Medical Oncology, Hospital Universitario Carlos Haya, Málaga, Spain. [Marcuello,E] Department of Medical Oncology, Hospital Santa Creu i Sant Pau, Barcelona, Spain. [Cervantes,A] Department of Medical Oncology, Institute of Health Research INCLIVA. University of Valencia, Valencia, Spain. [Martínez de Prado, P] Department of Medical Oncology, Hospital de Basurto, Vizcaya, Spain. [Fernández-Martos, C] Department of Medical Oncology, Instituto Valenciano de Oncología, Valencia, Spain. [Arrivi,A] Department of Medical Oncology, Fundación Hospital Son Llatzer, Palma de Mallorca, Spain., and This work was supported by Roche
- Subjects
Male ,Oncology ,Organoplatinum Compounds ,endocrine system diseases ,Epidemiology ,Colorectal cancer ,Named Groups::Persons::Age Groups::Adult::Middle Aged [Medical Subject Headings] ,Deoxycytidine ,Metastasis ,Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings] ,Antineoplastic Combined Chemotherapy Protocols ,Pathology ,Medicine ,Neoplasm Metastasis ,genes ,lcsh:Science ,mediana edad ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Clinical Protocols::Antineoplastic Protocols::Antineoplastic Combined Chemotherapy Protocols [Medical Subject Headings] ,Aged, 80 and over ,anciano ,Chemicals and Drugs::Organic Chemicals::Organometallic Compounds::Organoplatinum Compounds [Medical Subject Headings] ,Cancer Risk Factors ,Clinical Pharmacology ,protocolos de quimioterapia antineoplásica combinada ,Colon Adenocarcinoma ,Pronóstico ,Combination chemotherapy ,adulto ,Prognosis ,Bevacizumab ,Oxaliplatin ,pronóstico ,Oncology Agents ,medicine.medical_specialty ,Phenomena and Processes::Genetic Phenomena::Genetic Variation::Mutation [Medical Subject Headings] ,Fluorouracilo ,Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds, 1-Ring::Pyrimidines::Pyrimidine Nucleosides::Cytidine::Deoxycytidine [Medical Subject Headings] ,Check Tags::Male [Medical Subject Headings] ,Molecular Genetics ,Capecitabine ,Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal::Antibodies, Monoclonal, Humanized [Medical Subject Headings] ,Gastrointestinal Tumors ,Genetics ,Named Groups::Persons::Age Groups::Adult [Medical Subject Headings] ,Humans ,Clinical Trials ,Biology ,neoplasms ,Aged ,lcsh:R ,Diseases::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms [Medical Subject Headings] ,Phenomena and Processes::Genetic Phenomena::Genetic Structures::Genome::Genome Components::Genes::Genes, Neoplasm::Oncogenes::Proto-Oncogenes::Genes, ras [Medical Subject Headings] ,medicine.disease ,digestive system diseases ,Check Tags::Female [Medical Subject Headings] ,Pharmacogenetics ,Mutation ,lcsh:Q ,fluorouracilo ,Multivariate analysis ,Desoxicitidina ,humanos ,Cancer Treatment ,Named Groups::Persons::Age Groups::Adult::Aged::Aged, 80 and over [Medical Subject Headings] ,lcsh:Medicine ,medicine.disease_cause ,Neoplasias colorrectales ,Surgical oncology ,Basic Cancer Research ,Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds, 1-Ring::Pyrimidines::Pyrimidinones::Uracil::Fluorouracil [Medical Subject Headings] ,Clinical Trials (Cancer Treatment) ,metástasis neoplásica ,Metástasis neoplásica ,Multidisciplinary ,Middle Aged ,Genetic Epidemiology ,Protocolos de quimioterapia antineoplásica combinada ,Female ,Antiangiogenesis Therapy ,Fluorouracil ,KRAS ,Colorectal Neoplasms ,Research Article ,medicine.drug ,Adult ,Drugs and Devices ,Clinical Pathology ,neoplasias colorrectales ,Clinical Research Design ,Genetic Causes of Cancer ,Antibodies, Monoclonal, Humanized ,Antibodies ,Rectal Cancer ,Antibody Therapy ,Diagnostic Medicine ,Internal medicine ,Diseases::Neoplasms::Neoplastic Processes::Neoplasm Metastasis [Medical Subject Headings] ,Named Groups::Persons::Age Groups::Adult::Aged [Medical Subject Headings] ,mutación ,Clinical Genetics ,Mutación ,business.industry ,Pharmacoepidemiology ,Cancers and Neoplasms ,Human Genetics ,Chemotherapy and Drug Treatment ,desoxicitidina ,Genes, ras ,anticuerpos ,Genetics of Disease ,business ,compuestos organoplatino - Abstract
Background: In the MACRO study, patients with metastatic colorectal cancer (mCRC) were randomised to first-line treatment with 6 cycles of capecitabine and oxaliplatin (XELOX) plus bevacizumab followed by either single-agent bevacizumab or XELOX plus bevacizumab until disease progression. An additional retrospective analysis was performed to define the prognostic value of tumour KRAS status on progression-free survival (PFS), overall survival (OS) and response rates. Methodology/Principal Findings: KRAS data (tumour KRAS status and type of mutation) were collected by questionnaire from participating centres that performed KRAS analyses. These data were then cross-referenced with efficacy data for relevant patients in the MACRO study database. KRAS status was analysed in 394 of the 480 patients (82.1%) in the MACRO study. Wild-type (WT) KRAS tumours were found in 219 patients (56%) and mutant (MT) KRAS in 175 patients (44%). Median PFS was 10.9 months for patients with WT KRAS and 9.4 months for patients with MT KRAS tumours (p = 0.0038; HR: 1.40; 95% CI: 1.12-1.77). The difference in OS was also significant: 26.7 months versus 18.0 months for WT versus MT KRAS, respectively (p = 0.0002; HR: 1.55; 95% CI: 1.23-1.96). Univariate and multivariate analyses showed that KRAS was an independent variable for both PFS and OS. Responses were observed in 126 patients (57.5%) with WT KRAS tumours and 76 patients (43.4%) with MT KRAS tumours (p = 0.0054; OR: 1.77; 95% CI: 1.18-2.64). Conclusions/Significance: This analysis of the MACRO study suggests a prognostic role for tumour KRAS status in patients with mCRC treated with XELOX plus bevacizumab. For both PFS and OS, KRAS status was an independent factor in univariate and multivariate analyses., This work was supported by Roche (www.roche.es) The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
- Published
- 2012
35. Systematic Review and Meta-Analyses of Aminopeptidases as Prognostic Biomarkers in Amyotrophic Lateral Sclerosis.
- Author
-
Teruel-Peña B, Gómez-Urquiza JL, Suleiman-Martos N, Prieto I, García-Cózar FJ, Ramírez-Sánchez M, Fernández-Martos C, and Domínguez-Vías G
- Subjects
- Humans, Aminopeptidases, Genome-Wide Association Study, Prognosis, Biomarkers, Amyotrophic Lateral Sclerosis diagnosis, Amyotrophic Lateral Sclerosis genetics, Neurodegenerative Diseases
- Abstract
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by the progressive loss of motor neurons in the spinal cord, brain stem, and cerebral cortex. Biomarkers for ALS are essential for disease detection and to provide information on potential therapeutic targets. Aminopeptidases catalyze the cleavage of amino acids from the amino terminus of protein or substrates such as neuropeptides. Since certain aminopeptidases are known to increase the risk of neurodegeneration, such mechanisms may reveal new targets to determine their association with ALS risk and their interest as a diagnostic biomarker. The authors performed a systematic review and meta-analyses of genome-wide association studies (GWASs) to identify reported aminopeptidases genetic loci associated with the risk of ALS. PubMed, Scopus, CINAHL, ISI Web of Science, ProQuest, LILACS, and Cochrane databases were searched to retrieve eligible studies in English or Spanish, published up to 27 January 2023. A total of 16 studies were included in this systematic review, where a series of aminopeptidases could be related to ALS and could be promising biomarkers (DPP1, DPP2, DPP4, LeuAP, pGluAP, and PSA/NPEPPS). The literature reported the association of single-nucleotide polymorphisms (SNPs: rs10260404 and rs17174381) with the risk of ALS. The genetic variation rs10260404 in the DPP6 gene was identified to be highly associated with ALS susceptibility, but meta-analyses of genotypes in five studies in a matched cohort of different ancestry (1873 cases and 1861 control subjects) showed no ALS risk association. Meta-analyses of eight studies for minor allele frequency (MAF) also found no ALS association for the "C" allele. The systematic review identified aminopeptidases as possible biomarkers. However, the meta-analyses for rs1060404 of DPP6 do not show a risk associated with ALS.
- Published
- 2023
- Full Text
- View/download PDF
36. A Phase I-II multicenter trial with Avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients; GEMCAD 1602 study.
- Author
-
Español-Rego M, Fernández-Martos C, Elez E, Foguet C, Pedrosa L, Rodríguez N, Ruiz-Casado A, Pineda E, Cid J, Cabezón R, Oliveres H, Lozano M, Ginés A, García-Criado A, Ayuso JR, Pagés M, Cuatrecasas M, Torres F, Thomson T, Cascante M, Benítez-Ribas D, and Maurel J
- Subjects
- Humans, DNA Mismatch Repair, Dendritic Cells, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Cancer Vaccines therapeutic use, Colorectal Neoplasms, Colonic Neoplasms drug therapy, Rectal Neoplasms drug therapy
- Abstract
Background: Immune check-point blockade (ICB) has shown clinical benefit in mismatch repair-deficient/microsatellite instability high metastatic colorectal cancer (mCRC) but not in mismatch repair-proficient/microsatellite stable patients. Cancer vaccines with autologous dendritic cells (ADC) could be a complementary therapeutic approach to ICB as this combination has the potential to achieve synergistic effects., Methods: This was a Phase I/II multicentric study with translational sub-studies, to evaluate the safety, pharmacodynamics and anti-tumor effects of Avelumab plus ADC vaccine in heavily pre-treated MSS mCRC patients. Primary objective was to determine the maximum tolerated dose and the efficacy of the combination. The primary end-point was 40% progression-free survival at 6 months with a 2 Simon Stage., Results: A total of 28 patients were screened and 19 pts were included. Combined therapy was safe and well tolerated. An interim analysis (Simon design first-stage) recommended early termination because only 2/19 (11%) patients were disease free at 6 months. Median PFS was 3.1 months [2.1-5.3 months] and overall survival was 12.2 months [3.2-23.2 months]. Stimulation of immune system was observed in vitro but not clinically. The evaluation of basal RNA-seq noted significant changes between pre and post-therapy liver biopsies related to lipid metabolism and transport, inflammation and oxidative stress pathways., Conclusions: The combination of Avelumab plus ADC vaccine is safe and well tolerated but exhibited modest clinical activity. Our study describes, for the first-time, a de novo post-therapy metabolic rewiring, that could represent novel immunotherapy-induced tumor vulnerabilities., (© 2022. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
37. Clinical Impact of Presurgery Circulating Tumor DNA after Total Neoadjuvant Treatment in Locally Advanced Rectal Cancer: A Biomarker Study from the GEMCAD 1402 Trial.
- Author
-
Vidal J, Casadevall D, Bellosillo B, Pericay C, Garcia-Carbonero R, Losa F, Layos L, Alonso V, Capdevila J, Gallego J, Vera R, Salud A, Martin-Richard M, Nogué M, Cillán E, Maurel J, Faull I, Raymond V, Fernández-Martos C, and Montagut C
- Subjects
- Adult, Aged, Antineoplastic Combined Chemotherapy Protocols adverse effects, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Combined Modality Therapy, Female, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Neoadjuvant Therapy, Neoplasm Metastasis, Neoplasm Recurrence, Local, Neoplasm Staging, Prognosis, Rectal Neoplasms mortality, Rectal Neoplasms therapy, Treatment Outcome, Biomarkers, Tumor, Circulating Tumor DNA, Preoperative Period, Rectal Neoplasms blood, Rectal Neoplasms diagnosis
- Abstract
Purpose: Total neoadjuvant treatment (TNT) is a valid strategy for patients with high-risk locally advanced rectal cancer (LARC). Biomarkers of response to TNT are an unmet clinical need. We aimed to determine the value of circulating tumor DNA (ctDNA) to predict tumor response, recurrence, and survival in patients with LARC treated with TNT., Experimental Design: The GEMCAD 1402 was a phase II randomized, multicentric clinical trial that randomized 180 patients with LARC to modified schedule of fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) +/- aflibercept, followed by chemoradiation and surgery. Plasma samples were collected at baseline and after TNT within 48 hours before surgery (presurgery). An ultrasensitive assay that integrates genomic and epigenomic cancer signatures was used to assess ctDNA status. ctDNA results were correlated with variables of local tumor response in the surgery sample, local/systemic recurrence, and survival., Results: A total of 144 paired plasma samples from 72 patients were included. ctDNA was detectable in 83% of patients at baseline and in 15% following TNT (presurgery). No association was found between ctDNA status and pathologic response. Detectable presurgery ctDNA was significantly associated with systemic recurrence, shorter disease-free survival (HR, 4; P = 0.033), and shorter overall survival (HR, 23; P < 0.0001)., Conclusions: In patients with LARC treated with TNT, presurgery ctDNA detected minimal metastatic disease identifying patients at high risk of distant recurrence and death. This study sets the basis for prospective clinical trials that use liquid biopsy to personalize the therapeutic approach following TNT., (©2021 American Association for Cancer Research.)
- Published
- 2021
- Full Text
- View/download PDF
38. Clinical Impact of Circulating Tumor RAS and BRAF Mutation Dynamics in Patients With Metastatic Colorectal Cancer Treated With First-Line Chemotherapy Plus Anti-Epidermal Growth Factor Receptor Therapy.
- Author
-
Maurel J, Alonso V, Escudero P, Fernández-Martos C, Salud A, Méndez M, Gallego J, Rodriguez JR, Martín-Richard M, Fernández-Plana J, Manzano H, Méndez JC, Zanui M, Falcó E, Gil-Raga M, Aparicio J, Feliu J, García-Albéniz X, Torres F, Rojo F, Bellosillo B, Mendiola M, Fernández V, Reig O, Claes B, Maertens G, Sablon E, Jacobs B, and Montagut C
- Abstract
Purpose: RAS and BRAF mutations can be detected as a mechanism of acquired resistance in circulating tumor (ct) DNA in patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor therapy., Methods: RAS and BRAF mutational status was assessed in ctDNA in a baseline plasma sample and a serum sample collected at the time of the last available determination (named secondary extraction) from patients with KRAS exon 2 wild-type metastatic colorectal cancer treated in two first-line prospective biomarker-designed clinical trials (PULSE, ClinicalTrials.gov identifier: NCT01288339; and POSIBA, ClincialTrials.gov identifier: NCT01276379)., Results: Analysis of extended RAS and BRAF in tissue and plasma from 178 patients with KRAS exon 2 wild-type metastatic colorectal cancer showed a sensitivity of 64.1% and a specificity of 90%. The median overall survival (OS) of baseline patients with RAS and BRAF mutations in ctDNA was 22.3 months (95% CI, 15.6 to 29 months) and 8.9 months (95% CI, 6.3 to 11.4 months), respectively, which was significantly inferior to the median OS of 40.4 months (95% CI, 35.9 to 44.9 months) in two patients with wild-type disease ( P < .001). Acquisition of RAS/BRAF mutations occurred in nine of 63 patients (14%) with progressive disease (PD; ie, blood draw within 1 month before PD or after PD) compared with six of 73 patients (8%) with no PD or blood extraction for ctDNA analysis before 1 month of PD ( P = .47). Median OS in patients with RAS/BRAF acquisition was 23.9 months (95% CI, 19.7 to 27.9 months) compared with 40.6 months (95% CI, not reached to not reached) in patients who remained free of mutations ( P = .016)., Conclusion: Our results confirm that baseline RAS and BRAF testing in ctDNA discriminates survival. The emergence of RAS/BRAF mutations has limited relevance for the time to progression to anti-epidermal growth factor receptor therapy.
- Published
- 2019
- Full Text
- View/download PDF
39. Effect of Aflibercept Plus Modified FOLFOX6 Induction Chemotherapy Before Standard Chemoradiotherapy and Surgery in Patients With High-Risk Rectal Adenocarcinoma: The GEMCAD 1402 Randomized Clinical Trial.
- Author
-
Fernández-Martos C, Pericay C, Losa F, García-Carbonero R, Layos L, Rodríguez-Salas N, Martin-Richard M, Alonso-Orduña V, Vera R, Gallego J, Capdevila J, Salud A, Nogué M, Maurel J, Guash I, Montagut C, Lopez C, Macias I, Jain RK, and Garcia-Albeniz X
- Abstract
Importance: Preclinical studies suggest that a vascular endothelial growth factor (VEGF) blockade may play a role in the preoperative treatment of rectal adenocarcinoma; however, how to combine anti-VEGF drugs with neoadjuvant chemotherapy (CT) and/or chemoradiotherapy (CRT) remains controversial., Objective: To study the effect of aflibercept plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) induction CT prior to standard CRT and total mesorectal excision (TME) surgery in patients with high-risk rectal adenocarcinoma., Design, Setting, and Participants: In the Grupo Español Multidisciplinar En Cancer Digestivo (GEMCAD) 1402 phase 2 randomized clinical trial, 180 patients aged 18 to 75 years, identified by centrally reviewed magnetic resonance imaging to have mrT3c-d/T4/N2 rectal adenocarcinoma, were enrolled from 20 treatment centers in Spain between January 2015 and March 2017. Patients were randomized in a 2:1 treatment to control arm ratio. The primary end point was evaluated at 2 interim and 1 final analyses. The study was designed to perform hypothesis testing at α = .2 and β = .2. A 2-sided P value of <.1984 in the final analysis of the intention-to-treat population was the threshold for considering the experimental treatment to be more effective than the control., Interventions: Patients received neoadjuvant mFOLFOX6 with (arm A; n = 115) or without (arm B; n = 65) aflibercept, 4 mg/kg (every 2 weeks, 6 cycles, and 3 months) prior to standard CRT and TME surgery., Main Outcomes and Measures: The primary end point was a pathologic complete response (pCR) (ypT0N0). Secondary end points included toxic effects, surgical morbidity, R0 resections, compliance, and 3-year disease-free survival., Results: For the 115 patients who received treatment with mFOLFOX6 plus aflibercept, the median (range) age was 60 (32-75) years, 77 men (66.9%) and 38 women (33.0%). For the 65 patients who received induction CT treatment with only mFOLFOX6, the median (range) age was 65 (39-75) years, 39 men (60.0%) and 26 women (40.0%). The pCR rate in the intention-to-treat population was 22.6% (95% CI, 15.3%-31.3%) in arm A and 13.8% (95% CI, 6.5%-24.6%) in arm B (P = .15). The main differential toxic effect was grade 3/4 hypertension during the induction phase. Postoperative complications were similar in both arms (15.5% in arm A and 12.9% in arm B). A total of 106 patients (92.1%) in arm A and 63 (96.9%) in arm B received all treatment cycles., Conclusions and Relevance: The study met its primary end point. The findings suggest that adding aflibercept to an induction regimen using mFOLFOX6 plays a role in increasing the pCR rate in patients with high-risk rectal adenocarcinoma, without substantially increasing surgical complications. The GEMCAD 1402 trial provides a rationale for phase 3 trials., Trial Registration: ClinicalTrials.gov identifier: NCT02340949.
- Published
- 2019
- Full Text
- View/download PDF
40. Coexpression of p-IGF-1R and MMP-7 Modulates Panitumumab and Cetuximab Efficacy in RAS Wild-Type Metastatic Colorectal Cancer Patients.
- Author
-
Alonso V, Escudero P, Fernández-Martos C, Salud A, Méndez M, Gallego J, Rodriguez JR, Martín-Richard M, Fernández-Plana J, Manzano H, Méndez JC, Zanui M, Falcó E, Gil-Raga M, Rojo F, Cuatrecasas M, Feliu J, García-Albéniz X, and Maurel J
- Subjects
- Aged, Colorectal Neoplasms drug therapy, Colorectal Neoplasms metabolism, Female, Humans, Kaplan-Meier Estimate, Male, Matrix Metalloproteinase 7 metabolism, Middle Aged, Mutation, Panitumumab, Prognosis, Proportional Hazards Models, Proto-Oncogene Proteins B-raf genetics, Receptor, IGF Type 1 metabolism, Antibodies, Monoclonal pharmacology, Cetuximab pharmacology, Colorectal Neoplasms genetics, Colorectal Neoplasms pathology, Gene Expression, Matrix Metalloproteinase 7 genetics, Receptor, IGF Type 1 genetics, ras Proteins genetics
- Abstract
Introduction: The coexpression of pIGF-1R and MMP-7 (double-positive phenotype, DP) correlates with poor overall survival (OS) in KRAS wild-type (WT) (exon 2) metastatic colorectal cancer (mCRC) patients treated with irinotecan-cetuximab in second/third line., Methods: We analyzed two prospective biomarker design trials of newly diagnosed RAS-WT mCRC patients treated with panitumumab-FOLFOX6 (PULSE trial; NCT01288339) or cetuximab plus either FOLFOX6/FOLFIRI (POSIBA trial; NCT01276379). The main exposure was DP phenotype (DP/non-DP), as assessed by two independent pathologists. DP cases were defined by immunohistochemistry as >70% expression of moderate or strong intensity for both MMP-7 and pIGF-1R. Primary endpoint: progression-free survival (PFS); secondary endpoints: OS and response rate. PFS and OS were adjusted by baseline characteristics using multivariate Cox models., Results: We analyzed 67 patients (30 non-DP, 37 DP) in the PULSE trial and 181 patients in the POSIBA trial (158 non-DP, 23 DP). Response rates and PFS were similar between groups in both studies. DP was associated with prolonged OS in PULSE (adjusted HR: 0.23; 95%CI: 0.11-0.52; P=.0004) and with shorter OS in POSIBA (adjusted HR: 1.67; 95%CI: 0.96-2.90; P=.07)., Conclusion: A differential effect of anti-EGFRs on survival by DP phenotype was observed. Panitumumab might be more beneficial for RAS-WT mCRC patients with DP phenotype, whereas cetuximab might improve OS in non-DP., (Copyright © 2018. Published by Elsevier Inc.)
- Published
- 2018
- Full Text
- View/download PDF
41. Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer.
- Author
-
Codony-Servat J, Cuatrecasas M, Asensio E, Montironi C, Martínez-Cardús A, Marín-Aguilera M, Horndler C, Martínez-Balibrea E, Rubini M, Jares P, Reig O, Victoria I, Gaba L, Martín-Richard M, Alonso V, Escudero P, Fernández-Martos C, Feliu J, Méndez JC, Méndez M, Gallego J, Salud A, Rojo F, Castells A, Prat A, Rosell R, García-Albéniz X, Camps J, and Maurel J
- Subjects
- Aged, Antibodies, Monoclonal administration & dosage, Antibodies, Monoclonal pharmacology, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Bevacizumab administration & dosage, Camptothecin administration & dosage, Camptothecin analogs & derivatives, Cell Survival drug effects, Cetuximab administration & dosage, Colorectal Neoplasms genetics, Colorectal Neoplasms pathology, Curcumin pharmacology, Dasatinib pharmacology, Fatty Acids, Unsaturated pharmacology, Female, Fluorouracil administration & dosage, Fluorouracil pharmacology, Gene Silencing, HCT116 Cells, HT29 Cells, Humans, Leucovorin administration & dosage, Male, Middle Aged, Molecular Chaperones genetics, Molecular Chaperones metabolism, Molecular Targeted Therapy, Niacinamide analogs & derivatives, Niacinamide pharmacology, Organoplatinum Compounds administration & dosage, Organoplatinum Compounds pharmacology, Oxaliplatin, Panitumumab, Phenylurea Compounds pharmacology, Protein Inhibitors of Activated STAT genetics, Protein Inhibitors of Activated STAT metabolism, Proto-Oncogene Proteins B-raf genetics, Proto-Oncogene Proteins p21(ras) genetics, Pyrimidines pharmacology, Pyrroles pharmacology, Signal Transduction drug effects, Sorafenib, Antineoplastic Agents pharmacology, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Cell Nucleus metabolism, Colorectal Neoplasms drug therapy, Drug Resistance, Neoplasm, Protein Transport drug effects, Receptor, IGF Type 1 metabolism
- Abstract
Background: Although chemotherapy is the cornerstone treatment for patients with metastatic colorectal cancer (mCRC), acquired chemoresistance is common and constitutes the main reason for treatment failure. Monoclonal antibodies against insulin-like growth factor-1 receptor (IGF-1R) have been tested in pre-treated mCRC patients, but results have been largely deceiving., Methods: We analysed time to progression, overall survival, and the mutational status of RAS, BRAF and nuclear p-IGF-1R expression by immunohistochemistry, in 470 metastatic CRC patients. The effect of IGF-1R activation and distribution was also assessed using cellular models of CRC and RNAi for functional validation., Results: Nuclear IGF-1R increased in metastatic tumours compared to paired untreated primary tumours, and significantly correlated with poor overall survival in mCRC patients. In vitro, chemo-resistant cell lines presented significantly higher levels of IGF-1R expression within the nuclear compartment, and PIAS3, a protein implicated also in the sumoylation process of intranuclear proteins, contributed to IGF-1R nuclear sequestration, highlighting the essential role of PIAS3 in this process. Intriguingly, we observed that ganitumab, an IGF-1R blocking-antibody used in several clinical trials, and dasatinib, an SRC inhibitor, increased the nuclear localisation of IGF-1R., Conclusions: Our study demonstrates that IGF-1R nuclear location might lead to chemotherapy and targeted agent resistance.
- Published
- 2017
- Full Text
- View/download PDF
42. [Histological factors predicting loco-regional lymph node metastasis in early invasive colorectal adenocarcinoma pT1].
- Author
-
Machado I, Valera-Alberni M, Martínez de Juan F, López-Guerrero JA, García Fadrique A, Cruz J, Martínez Lapiedra C, de Alcantara FM, Yaya R, Campos J, Fernández-Martos C, and Estevan R
- Subjects
- Adenoma, Humans, Lymph Nodes pathology, Prognosis, Risk Factors, Adenocarcinoma pathology, Colorectal Neoplasms pathology, Lymphatic Metastasis diagnosis, Neoplasm Invasiveness
- Abstract
Introduction: Endoscopic resection is the common treatment in pT1 colorectal adenocarcinoma whenever possible. The presence of adverse histological factors requires subsequent lymph node evaluation., Materials and Methods: We selected 29 colorectal pT1 adenocarcinoma including endoscopic polypectomies and the corresponding surgical specimens. All histologic parameters associated with N+ were evaluated by 2 pathologists, including: tumor differentiation grade, depth of invasion in the submucosa, angiolymphatic invasion (ALI), perineural invasion, chronic inflammation, tumor budding, poorly differentiated cluster, pre-existing adenoma, tumor border, and endoscopic resection margin. Univariate and multivariate logistic regression analysis were performed to assess the individual capacity of each variable to predict N+., Results: In the univariate analysis, rectal tumor localization, ALI and poorly differentiated cluster was significantly associated with N+. Among the significant parameters, ALI had the highest area under the ROC curve (0.875). Multivariate analysis showed no independent variables associated with N+., Conclusions: We confirm that ALI and the presence of poorly differentiated cluster are frequently associated with N+ in early colorectal cancer. Consequently, these parameters should be routinely evaluated by pathologists., (Copyright © 2015 Elsevier España, S.L.U. and AEEH y AEG. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
43. ColoLipidGene: signature of lipid metabolism-related genes to predict prognosis in stage-II colon cancer patients.
- Author
-
Vargas T, Moreno-Rubio J, Herranz J, Cejas P, Molina S, González-Vallinas M, Mendiola M, Burgos E, Aguayo C, Custodio AB, Machado I, Ramos D, Gironella M, Espinosa-Salinas I, Ramos R, Martín-Hernández R, Risueño A, De Las Rivas J, Reglero G, Yaya R, Fernández-Martos C, Aparicio J, Maurel J, Feliu J, and Ramírez de Molina A
- Subjects
- 1-Acylglycerol-3-Phosphate O-Acyltransferase genetics, 1-Acylglycerol-3-Phosphate O-Acyltransferase metabolism, ATP Binding Cassette Transporter 1 genetics, ATP Binding Cassette Transporter 1 metabolism, Adult, Aged, Aged, 80 and over, Basic Helix-Loop-Helix Transcription Factors genetics, Basic Helix-Loop-Helix Transcription Factors metabolism, Cell Proliferation, Colorectal Neoplasms metabolism, Disease-Free Survival, Female, Humans, Male, Middle Aged, Neoplasm Staging, Prognosis, Proportional Hazards Models, Recurrence, Regression Analysis, Retrospective Studies, Stearoyl-CoA Desaturase genetics, Stearoyl-CoA Desaturase metabolism, Time Factors, Treatment Outcome, Colorectal Neoplasms diagnosis, Colorectal Neoplasms genetics, Gene Expression Profiling, Gene Expression Regulation, Neoplastic, Lipid Metabolism
- Abstract
Lipid metabolism plays an essential role in carcinogenesis due to the requirements of tumoral cells to sustain increased structural, energetic and biosynthetic precursor demands for cell proliferation. We investigated the association between expression of lipid metabolism-related genes and clinical outcome in intermediate-stage colon cancer patients with the aim of identifying a metabolic profile associated with greater malignancy and increased risk of relapse. Expression profile of 70 lipid metabolism-related genes was determined in 77 patients with stage II colon cancer. Cox regression analyses using c-index methodology was applied to identify a metabolic-related signature associated to prognosis. The metabolic signature was further confirmed in two independent validation sets of 120 patients and additionally, in a group of 264 patients from a public database. The combined analysis of these 4 genes, ABCA1, ACSL1, AGPAT1 and SCD, constitutes a metabolic-signature (ColoLipidGene) able to accurately stratify stage II colon cancer patients with 5-fold higher risk of relapse with strong statistical power in the four independent groups of patients. The identification of a group of 4 genes that predict survival in intermediate-stage colon cancer patients allows delineation of a high-risk group that may benefit from adjuvant therapy, and avoids the toxic and unnecessary chemotherapy in patients classified as low-risk group.
- Published
- 2015
- Full Text
- View/download PDF
44. Soluble FAS in the prediction of benefit from cetuximab and irinotecan for patients with advanced colorectal cancer.
- Author
-
Codony-Servat J, Garcia-Albeniz X, Pericay C, Alonso V, Escudero P, Fernández-Martos C, Gallego R, Martínez-Cardús A, Martinez-Balibrea E, and Maurel J
- Subjects
- Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized administration & dosage, Blotting, Western, Camptothecin administration & dosage, Camptothecin analogs & derivatives, Cell Line, Tumor, Cetuximab, Colorectal Neoplasms mortality, Disease-Free Survival, Enzyme-Linked Immunosorbent Assay, Fas Ligand Protein blood, Female, Humans, Irinotecan, Kaplan-Meier Estimate, Male, Middle Aged, Proportional Hazards Models, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Biomarkers, Tumor blood, Colorectal Neoplasms blood, Colorectal Neoplasms drug therapy, fas Receptor blood
- Abstract
The FAS/FASL system, comprising membrane-bound (mFAS and mFASL) and soluble forms (sFAS and sFASL), has been related to apoptosis driven by chemotherapy administration. In vitro experiments show chemotherapy upregulating membrane-bound forms, leading to an increase of receptor availability (at 24-72 h) and favoring apoptosis. The regulatory effect of chemotherapy on sFAS in patients has never been explored prospectively in advanced colorectal cancer (ACRC). We performed a pharmacodynamic study to address sFAS/sFASL variation. A prospective phase II translational multicenter study was designed to evaluate progression-free rate (PFR) in patients with ACRC treated with irinotecan and cetuximab in third-line therapy. The effect of sFAS was studied in vitro in colorectal cancer cell lines. Our results showed that statistically significant changes were observed in sFAS at 24-72 h compared to baseline levels in the pharmacodynamic study. Of the 93 patients enrolled in the prospective study in third-line therapy with cetuximab-irinotecan, 85 were evaluated for sFAS/sFASL changes at 48 h. There was no difference in PFR at 4 months between patients with sFAS and sFASL changes. In vitro analysis showed that although LoVo cell lines were sensitive to oxaliplatin and fluorouracil due to modulation of sFAS and FAS, HT29 lines were not. In summary, chemotherapy regulates FAS soluble fractions in vitro and in vivo, but does not predict PFR in ACRC patients undergoing third-line therapy with the combination of cetuximab and irinotecan.
- Published
- 2013
- Full Text
- View/download PDF
45. Upregulation of trefoil factor 3 (TFF3) after rectal cancer chemoradiotherapy is an adverse prognostic factor and a potential therapeutic target.
- Author
-
Casado E, Garcia VM, Sánchez JJ, Gómez Del Pulgar MT, Feliu J, Maurel J, Castelo B, Moreno Rubio J, López RA, García-Cabezas MÁ, Burgos E, de Castro J, Belda-Iniesta C, López-Gómez M, Gómez-Raposo C, Zambrana F, Sereno M, Fernández-Martos C, Vázquez P, Lacal JC, González-Barón M, and Cejas P
- Subjects
- Adenocarcinoma genetics, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Cell Line, Tumor, Disease-Free Survival, Drug Resistance, Neoplasm genetics, Female, Gene Expression Profiling methods, Humans, Male, Middle Aged, Multivariate Analysis, Neoplasm Proteins genetics, Peptides genetics, Polymerase Chain Reaction, Prognosis, Protein Array Analysis methods, Rectal Neoplasms genetics, Retrospective Studies, Transfection methods, Trefoil Factor-3, Up-Regulation, Young Adult, Adenocarcinoma metabolism, Chemoradiotherapy, Adjuvant methods, Neoplasm Proteins metabolism, Neoplasm Recurrence, Local, Peptides metabolism, Rectal Neoplasms metabolism, Rectal Neoplasms therapy
- Abstract
Purpose: Management of locally advanced rectal cancer (RC) consists of neoadjuvant chemoradiotherapy (CRT) with fluoropyrimidines, followed by total mesorectal excision. We sought to evaluate the expression of selected genes, some of which were derived from a previous undirected SAGE (serial analysis of gene expression)-based approach, before and after CRT, to identify mechanisms of resistance., Methods: This retrospective cohort study included 129 consecutive patients. Quantitative polymerase chain reaction of 53 candidate genes was performed on the biopsy specimen before treatment and on the surgical specimen after CRT. A paired-samples t test was performed to determine genes that were significantly changed after CRT. The result was correlated with patients' disease-free survival., Results: Twenty-two genes were significantly upregulated, and two were significantly downregulated. Several of the upregulated genes have roles in cell cycle control; these include CCNB1IP1, RCC1, EEF2, CDKN1, TFF3, and BCL2. The upregulation of TFF3 was associated with worse disease-free survival on multivariate analyses (hazard ratio, 2.64; P=.027). Patients whose surgical specimens immunohistochemically showed secretion of TFF3 into the lumen of the tumoral microglands had a higher risk of relapse (hazard ratio, 2.51; P=.014). In vitro experiments showed that DLD-1 cells stably transfected with TFF3 were significantly less sensitive to 5-fluorouracil and showed upregulation of genes involved in the transcriptional machinery and in resistance to apoptosis., Conclusion: Upregulation of TFF3 after CRT for RC is associated with a higher risk of relapse. The physiological role of TFF3 in restoring the mucosa during CRT could be interfering with treatment efficacy. Our results could reveal not only a novel RC prognostic marker but also a therapeutic target., (Copyright © 2012 Elsevier Inc. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
46. The role of capecitabine in locally advanced rectal cancer treatment: an update.
- Author
-
Fernández-Martos C, Nogué M, Cejas P, Moreno-García V, Machancoses AH, and Feliu J
- Subjects
- Capecitabine, Clinical Trials as Topic, Deoxycytidine therapeutic use, Fluorouracil therapeutic use, Humans, Neoadjuvant Therapy methods, Randomized Controlled Trials as Topic, Antineoplastic Agents therapeutic use, Deoxycytidine analogs & derivatives, Fluorouracil analogs & derivatives, Rectal Neoplasms drug therapy
- Abstract
Preoperative infusional 5-fluorouracil (5-FU) and concurrent radiation therapy (RT) followed by total mesorectal surgery is the current standard of care for locally advanced rectal cancer (LAR). When compared with postoperative 5-FU-based chemoradiation, this strategy is associated with significantly lower rates of local relapse, lower toxicity and better compliance. Capecitabine is a rationally designed oral prodrug that is converted into 5-FU by intracellular thymidine phosphorylase. Substitution of infusional 5-FU with capecitabine is an attractive option that provides a more convenient administration schedule and, possibly, increased efficacy. Indeed, incorporation of capecitabine in combined modality neoadjuvant therapy for LAR has been under intense investigation during the last 10 years. Phase I and II clinical trials showed that a regimen consisting of capecitabine 825mg/m(2) twice daily for 7 days/week continuous oral administration in combination with RT is an active and well tolerated regimen, thereby being the preferred concurrent regimen. The definitive demonstration that efficacy of capecitabine/RT is similar to 5-FU/RT has been provided by the NSABP-R-04 and the German Margit trials. One approach to improve outcomes in rectal cancer is to deliver a second RT-sensitizing drug with effective systemic activity. Oxaliplatin and irinotecan are therefore good candidates. However, two phase III trials demonstrated that incorporation of oxaliplatin to capecitabine with RT did not improve early outcomes and, by contrast, increased toxicity. Capecitabine has also been combined with irinotecan. This regimen showed encouraging results in phase I and II clinical trials, which led to an ongoing phase III clinical trial. New strategies with induction chemotherapy with or without chemoradiation prior to surgery are currently under investigation. Whether or not capecitabine has a role in this setting is being investigated in ongoing trials. Incorporation of agents directed towards new targets, such as anti-epidermal growth factor receptor (EGFR) antibodies or antiangiogenic agents, in combination preoperative regimens, is being hampered by results of early trials in which efficacy outcomes with cetuximab were poor and an excessive rate of surgical complications with bevacizumab was observed. The lack of improvements in efficacy with the addition of cetuximab or bevacizumab in the adjuvant treatment of colon cancer led to concerns about further development of these agents in rectal cancer. The role of capecitabine in the postoperative adjuvant setting is the aim of the ongoing Dutch SCRIPT trial. The prediction of response associated with capecitabine has been based on expression of thymidylate synthase and dihydropyrimidine dehydrogenase, as well as on gene expression arrays. All these procedures require further validation and should be considered as investigational. In conclusion, capecitabine can safely and effectively replace intravenous continuous infusion of 5-FU in the preoperative chemoradiation setting for rectal cancer management. The addition of other new antineoplastic agents to a fluoropyrimidine-based regimen remains investigational.
- Published
- 2012
- Full Text
- View/download PDF
47. Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish Cooperative Group for the Treatment of Digestive Tumors study.
- Author
-
Sastre J, Maestro ML, Gómez-España A, Rivera F, Valladares M, Massuti B, Benavides M, Gallén M, Marcuello E, Abad A, Arrivi A, Fernández-Martos C, González E, Tabernero JM, Vidaurreta M, Aranda E, and Díaz-Rubio E
- Subjects
- Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized administration & dosage, Antibodies, Monoclonal, Humanized adverse effects, Bevacizumab, Capecitabine, Colorectal Neoplasms pathology, Deoxycytidine administration & dosage, Deoxycytidine analogs & derivatives, Disease-Free Survival, Female, Fluorouracil administration & dosage, Fluorouracil analogs & derivatives, Humans, Male, Middle Aged, Neoplasm Metastasis, Organoplatinum Compounds administration & dosage, Oxaliplatin, Prognosis, Survival Analysis, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Colorectal Neoplasms blood, Colorectal Neoplasms drug therapy, Neoplastic Cells, Circulating pathology
- Abstract
Background: The Maintenance in Colorectal Cancer trial was a phase III study to assess maintenance therapy with single-agent bevacizumab versus bevacizumab plus chemotherapy in patients with metastatic colorectal cancer. An ancillary study was conducted to evaluate the circulating tumor cell (CTC) count as a prognostic and/or predictive marker for efficacy endpoints., Patients and Methods: One hundred eighty patients were included. Blood samples were obtained at baseline and after three cycles. CTC enumeration was carried out using the CellSearch® System (Veridex LLC, Raritan, NJ). Computed tomography scans were performed at cycle 3 and 6 and every 12 weeks thereafter for tumor response assessment., Results: The median progression-free survival (PFS) interval for patients with a CTC count ≥3 at baseline was 7.8 months, versus the 12.0 months achieved by patients with a CTC count <3 (p = .0002). The median overall survival (OS) time was 17.7 months for patients with a CTC count ≥3, compared with 25.1 months for patients with a lower count (p = .0059). After three cycles, the median PFS interval for patients with a low CTC count was 10.8 months, significantly longer than the 7.5 months for patients with a high CTC count (p = .005). The median OS time for patients with a CTC count <3 was significantly longer than for patients with a CTC count ≥3, 25.1 months versus 16.2 months, respectively (p = .0095)., Conclusions: The CTC count is a strong prognostic factor for PFS and OS outcomes in metastatic colorectal cancer patients.
- Published
- 2012
- Full Text
- View/download PDF
48. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study.
- Author
-
Díaz-Rubio E, Gómez-España A, Massutí B, Sastre J, Abad A, Valladares M, Rivera F, Safont MJ, Martínez de Prado P, Gallén M, González E, Marcuello E, Benavides M, Fernández-Martos C, Losa F, Escudero P, Arrivi A, Cervantes A, Dueñas R, López-Ladrón A, Lacasta A, Llanos M, Tabernero JM, Antón A, and Aranda E
- Subjects
- Adult, Aged, Aged, 80 and over, Angiogenesis Inhibitors administration & dosage, Antibodies, Monoclonal, Humanized administration & dosage, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Bevacizumab, Capecitabine, Colorectal Neoplasms pathology, Deoxycytidine administration & dosage, Deoxycytidine analogs & derivatives, Disease-Free Survival, Female, Fluorouracil administration & dosage, Fluorouracil analogs & derivatives, Humans, Induction Chemotherapy, Male, Middle Aged, Neoplasm Metastasis, Organoplatinum Compounds administration & dosage, Oxaliplatin, Oxaloacetates, Treatment Outcome, Angiogenesis Inhibitors therapeutic use, Antibodies, Monoclonal, Humanized therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Colorectal Neoplasms drug therapy
- Abstract
Purpose: The aim of this phase III trial was to compare the efficacy and safety of bevacizumab alone with those of bevacizumab and capecitabine plus oxaliplatin (XELOX) as maintenance treatment following induction chemotherapy with XELOX plus bevacizumab in the first-line treatment of patients with metastatic colorectal cancer (mCRC)., Patients and Methods: Patients were randomly assigned to receive six cycles of bevacizumab, capecitabine, and oxaliplatin every 3 weeks followed by XELOX plus bevacizumab or bevacizumab alone until progression. The primary endpoint was the progression-free survival (PFS) interval; secondary endpoints were the overall survival (OS) time, objective response rate (RR), time to response, duration of response, and safety., Results: The intent-to-treat population comprised 480 patients (XELOX plus bevacizumab, n = 239; bevacizumab, n = 241); there were no significant differences in baseline characteristics. The median follow-up was 29.0 months (range, 0-53.2 months). There were no statistically significant differences in the median PFS or OS times or in the RR between the two arms. The most common grade 3 or 4 toxicities in the XELOX plus bevacizumab versus bevacizumab arms were diarrhea, hand-foot syndrome, and neuropathy., Conclusion: Although the noninferiority of bevacizumab versus XELOX plus bevacizumab cannot be confirmed, we can reliably exclude a median PFS detriment >3 weeks. This study suggests that maintenance therapy with single-agent bevacizumab may be an appropriate option following induction XELOX plus bevacizumab in mCRC patients.
- Published
- 2012
- Full Text
- View/download PDF
49. Role of Kras status in patients with metastatic colorectal cancer receiving first-line chemotherapy plus bevacizumab: a TTD group cooperative study.
- Author
-
Díaz-Rubio E, Gómez-España A, Massutí B, Sastre J, Reboredo M, Manzano JL, Rivera F, Safont MJ, Montagut C, González E, Benavides M, Marcuello E, Cervantes A, Martínez de Prado P, Fernández-Martos C, Arrivi A, Bando I, and Aranda E
- Subjects
- Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized administration & dosage, Bevacizumab, Capecitabine, Colorectal Neoplasms genetics, Colorectal Neoplasms pathology, Deoxycytidine administration & dosage, Deoxycytidine analogs & derivatives, Female, Fluorouracil administration & dosage, Fluorouracil analogs & derivatives, Humans, Male, Middle Aged, Mutation, Organoplatinum Compounds administration & dosage, Oxaliplatin, Prognosis, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Colorectal Neoplasms drug therapy, Genes, ras, Neoplasm Metastasis
- Abstract
Background: In the MACRO study, patients with metastatic colorectal cancer (mCRC) were randomised to first-line treatment with 6 cycles of capecitabine and oxaliplatin (XELOX) plus bevacizumab followed by either single-agent bevacizumab or XELOX plus bevacizumab until disease progression. An additional retrospective analysis was performed to define the prognostic value of tumour KRAS status on progression-free survival (PFS), overall survival (OS) and response rates., Methodology/principal Findings: KRAS data (tumour KRAS status and type of mutation) were collected by questionnaire from participating centres that performed KRAS analyses. These data were then cross-referenced with efficacy data for relevant patients in the MACRO study database. KRAS status was analysed in 394 of the 480 patients (82.1%) in the MACRO study. Wild-type (WT) KRAS tumours were found in 219 patients (56%) and mutant (MT) KRAS in 175 patients (44%). Median PFS was 10.9 months for patients with WT KRAS and 9.4 months for patients with MT KRAS tumours (p=0.0038; HR: 1.40; 95% CI:1.12-1.77). The difference in OS was also significant: 26.7 months versus 18.0 months for WT versus MT KRAS, respectively (p=0.0002; HR: 1.55; 95% CI: 1.23-1.96). Univariate and multivariate analyses showed that KRAS was an independent variable for both PFS and OS. Responses were observed in 126 patients (57.5%) with WT KRAS tumours and 76 patients (43.4%) with MT KRAS tumours (p=0.0054; OR: 1.77; 95% CI: 1.18-2.64)., Conclusions/significance: This analysis of the MACRO study suggests a prognostic role for tumour KRAS status in patients with mCRC treated with XELOX plus bevacizumab. For both PFS and OS, KRAS status was an independent factor in univariate and multivariate analyses.
- Published
- 2012
- Full Text
- View/download PDF
50. APC and KRAS mutations in distal colorectal polyps are related to smoking habits in men: results of a cross-sectional study.
- Author
-
Martínez F, Fernández-Martos C, Quintana MJ, Castells A, Llombart A, Ińiguez F, Guillem V, and Dasí F
- Subjects
- Adenocarcinoma epidemiology, Adenocarcinoma genetics, Adenomatous Polyps epidemiology, Adenomatous Polyps genetics, Aged, Colorectal Neoplasms epidemiology, Colorectal Neoplasms genetics, Cross-Sectional Studies, DNA Mutational Analysis, Humans, Intestinal Polyps epidemiology, Male, Microsatellite Repeats genetics, Middle Aged, Prevalence, Proto-Oncogene Proteins p21(ras), Smoking epidemiology, Smoking genetics, Genes, APC, Intestinal Polyps genetics, Mutation, Proto-Oncogene Proteins genetics, Smoking adverse effects, ras Proteins genetics
- Abstract
Background: The purpose of this study was (a) to evaluate the association between cigarette smoking and the prevalence of distal colorectal polyps and adenocarcinoma and (b) to analyse genetic alterations representing different molecular pathways of the colorectal carcinogenesis., Methods: A total of 623 asymptomatic male (mean age: 53 years; 50-65) car factory workers were included. Information on smoking habits and other lifestyle factors were collected followed by a 60 cm colonoscopy. APC and KRAS mutations and microsatellite status were determined in colorectal lesions (colorectal carcinoma (CRC), hyperplastic (HP) and adenomatous polyps (AP)). Data were analysed using unconditional multiple logistic regression models., Results: Smokers had a higher prevalence of AP (OR 2.1; 95% CI 1.2-3.6; p<0.05) and HP (OR 5.4; 95% CI 2.6- 11.1; p<0.05). No differences in CRC were observed. There was a dose-response relationship with the number of cigarettes smoked. The risk of developing AP or HP decreased after smoking cessation, even among heavy smokers (≥20 packs/year). KRAS mutations were more prevalent among smokers AP (OR 5.6; 95% CI 1.6-20.4; p=0.007). There was a trend of positive association with APC mutations (OR 3.5; 95% CI 0.9-4.4; p=0.096). APC and KRAS mutations were found in 36% and 61% of the HP of smokers, but were absent in non-smokers (p=0.89 and 0.78, respectively). There were no differences in MSI between smokers and non-smokers., Conclusions: Cigarette smoking is associated with a higher risk of developing both HP and AP and a higher prevalence of mutations in APC and KRAS.
- Published
- 2011
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.